Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.42 |
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5682534 | 0.85 | MAPT (0.47) | GSK3BMAPTPTGS2TDP2NSD2 | |
| SCHEMBL27950468 | 0.73 | PTGS2 (0.69) | GSK3BPTGS2 | |
| SCHEMBL5683254 | 0.72 | GSK3B (0.47) | GSK3BALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30999951 | 0.71 | GSK3B (1.00) | GSK3BALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL5686101 | 0.71 | LMNA (0.49) | GSK3BALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL5682569 | 0.70 | CHRNA7 (0.49) | GSK3BALDH1A1MAPTPTGS2GAA | |
| SCHEMBL5683249 | 0.69 | MAPT (0.46) | GSK3BALDH1A1MAPTPTGS2HTT | |
| SCHEMBL6704189 | 0.68 | PTGS2 (0.58) | GSK3BALDH1A1MAPTPTGS2TDP2 | |
| SCHEMBL3816794 | 0.67 | GSK3B (0.67) | GSK3BPTGS2 | |
| SCHEMBL2056127 | 0.66 | GAA (0.63) | ALDH1A1MAPTALOX12KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040010031-A1 | Novel method and compounds | SMITHKLINE BEECHAM P.L.C. | 2004-01-15 | — | — | US | claimed |
| EP-1119548-A1 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | claimed |
| WO-2000021927-A2 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | claimed |
| US-20060252045-A1 | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | WYETH | 2006-11-09 | — | — | US | disclosed |
| WO-2005028678-A9 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH CORP (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1636388-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | Wyeth (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005028678-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH (US) | 2005-03-31 | — | — | WO | disclosed |
| US-6719520-B2 | FOR INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3); TREATMENT AND PROPHYLAXIS FOR DIABETES, CHRONIC NEURODEGENERATIVE CONDITIONS, MOOD DISORDERS SUCH AS SCHIZOPHRENIA AND MANIC DEPRESSION AND HAIR LOSS AND CANCER | SMITHKLINE BEECHAM CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040010031-A1 | Novel method and compounds | SMITHKLINE BEECHAM P.L.C. | 2004-01-15 | — | — | US | disclosed |
| EP-1119548-A1 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021927-A2 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010031-A1 | Novel method and compounds | GSK3A, GSK3B, GSKIP | GSK3B 2/4885ALDH1A1 2191/4885MAPT 72/4885 |
| US-20060252045-A1 | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | BMP4, BMP2, BMP6 | GSK3B 2078/4885ALDH1A1 3487/4885MAPT 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.